Uncategorized

Secretive Agios Makes Splash with $33M Series A

Agios Pharmaceuticals, backed by heavy hitters: Third Rock, Flagship and ARCH venture groups, announced it has closed a hefty, $33M Series A financing round.

There is very little substance in the press release or on the Agios website about the company or the technology.

The basic gist though, has to do with modulating the metabolism specific to cancer cells by preventing the hungry cells from breaking down glucose and other fuels.

$33M is a nice hall even for a Series B round so I’m sure there are some pretty hefty expectations at Agios this morning.

Theoretically Related Posts

• June 3, 2008 -- Funding Roundup: IRX, Genesis, Inimex, VeraLight and ONCODESIGN (0)
• August 25, 2008 -- Proteostasis Rakes in $45M in Series A (0)
• August 12, 2008 -- Heathcare / Medical Venture Capital Groups (0)
• June 23, 2008 -- Immune Design Nets $18M in Series A (0)
• April 30, 2008 -- Financing for Concert Pharmaceuticals (0)
• April 29, 2008 -- Financing for Nuon, Constellation and Neurologix (0)
• March 28, 2008 -- Pieris AG Nets 38M in Series B Financing (0)

© 2008 Pharmababble.